I. Torre-Salaberri

Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

S. Castañeda, E. Tomero, J. Troyano, 2020, Journal of clinical medicine.

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

M. González-Gay, J. Nolla, E. M. Muro, 2019, Arthritis & rheumatology.

Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.

J. Nolla, S. Castañeda, A. Adán, 2022, Seminars in arthritis and rheumatism.

FRI0269 COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHÇET’S DISEASE. NATIONAL MULTICENTER STUDY OF 177 CASES

F. Romero, J. Nolla, S. Castañeda, 2019, Poster Presentations.

AB1077 ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE

S. Castañeda, E. Tomero, R. Blanco, 2019, Abstracts Accepted for Publication.